Axsome Q3 2025 net product revenue $171M, up 63% YoY; submits sNDA for AXS-05 in Alzheimer's agitation

Axsome Therapeutics, Inc.

2025-Q3 EPS reported -$3.13 revenue$442,497,000

Total net product revenue $171.0M (63% YoY growth); AUVELITY $136.1M (+69%), SUNOSI $32.8M (+35%), SYMBRAVO $2.1M (first full quarter).
Net loss narrowed to $47.2M ($0.94/share) from $64.6M ($1.34/share) in Q3 2024; cash $325.3M.
Submitted sNDA for AXS-05 in Alzheimer's disease agitation (FDA Breakthrough Therapy); plans NDA submission for AXS-12 in narcolepsy in Q4 2025.
Pipeline: Phase 3 trials to initiate in Q4 2025 for AXS-05 (smoking cessation), solriamfetol (pediatric ADHD, MDD+EDS), and AXS-14 (fibromyalgia).
AUVELITY prescriptions ~209k in Q3 (+46% YoY); contracted with third large GPO; payer coverage ~85%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.